BD 672234 - PowerLoc Safety Infusion Set with Y-Injection Site, 22G x 0.75", 20/PK (Continental US Only)

BD 672234 - PowerLoc Safety Infusion Set with Y-Injection Site, 22G x 0.75", 20/PK (Continental US Only)

The BD 672234 PowerLoc Safety Infusion Set is a sterile, single-use port-access device designed for accessing compatible surgically implanted vascular ports. The set features a 22-gauge non-coring needle with a 0.75-inch length, an integrated Y-injection site, and approximately 8-inch tubing for flexible connection during infusion therapy and vascular-access procedures.

The PowerLoc system supports administration of compatible medications and fluids, blood specimen collection, implanted port flushing, and power injection through appropriately rated vascular-access systems. The 22-gauge configuration provides a smaller needle profile for applications where moderate flow capability is appropriate.

The 0.75-inch needle length is intended for implanted ports positioned relatively close to the skin surface. Correct needle-length selection helps support complete septum access, stable positioning, effective dressing application, and appropriate patient comfort.

The integrated Y-injection site provides an additional access point within the tubing for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway. This configuration uses approximately 8-inch tubing and has an approximate priming volume of 0.4 mL.

An integrated safety mechanism is designed to help reduce accidental needlestick exposure during port deaccessing. As the needle is withdrawn into the base, a safety shield covers the needle point and locks it into a protected position. Tactile feedback, an audible click, and visual confirmation help verify safety lockout before handling and disposal.

The PowerLoc platform features a compact, low-profile, lightweight design intended to facilitate dressing placement, maintain access-site visibility, and support efficient implanted port management. BD 672234 is supplied 20 sets per case.

Key Benefits

• 22-gauge non-coring needle supports access to compatible surgically implanted vascular ports.
• 0.75-inch needle length accommodates appropriately positioned superficial implanted ports.
• Smaller 22-gauge profile is suitable for applications where moderate flow capability meets clinical requirements.
• Power-injectable design supports compatible contrast-enhanced diagnostic imaging procedures.
• Maximum power-injection flow rate up to 2 mL per second when the complete vascular-access system is appropriately rated.
• Integrated Y-injection site provides secondary access for compatible medication, flushing, or fluid administration.
• Approximately 8-inch tubing provides practical working length for port-access procedures.
• Approximate 0.4 mL priming volume supports fluid-management planning.
• Non-coring needle design helps minimize unnecessary damage to compatible implanted port septa.
• Integrated safety mechanism covers and locks the needle point following port deaccessing.
• Tactile, audible, and visual indications help confirm safety lockout.
• Low-profile design helps facilitate appropriate dressing application.
• Small footprint supports visibility around the implanted port access site.
• Lightweight construction helps minimize unnecessary bulk at the access site.
• Ergonomic wing design supports controlled access and site visibility.
• Downward-angled tubing helps support dressing integrity.
• Adaptable for appropriate dual-lumen implanted port applications.
• 20-per-case packaging supports routine clinical inventory management.

Compatibility and Applications

The BD 672234 PowerLoc Safety Infusion Set is intended for use with compatible surgically implanted vascular-access ports designed to accept non-coring port-access needles.

Potential clinical applications include medication administration, antibiotic therapy, hydration, selected chemotherapy treatments, parenteral nutrition, blood specimen collection, implanted port flushing, long-term infusion therapy, and compatible contrast-media injection during diagnostic imaging procedures.

The 22-gauge configuration may be selected when a smaller needle profile and moderate flow capability meet the requirements of the prescribed therapy. Selection should consider medication or fluid characteristics, viscosity, required flow rate, implanted port specifications, infusion equipment, imaging requirements, and professional clinical judgment.

The 0.75-inch needle length is generally suitable for implanted ports positioned relatively close to the skin surface. A needle that is too short may not completely access the port septum, while unnecessary additional needle length may affect stability, securement, and dressing placement.

The integrated Y-injection site provides secondary access within the tubing. It may support compatible intermittent medication administration, flushing, or connection of another approved fluid pathway when permitted by the prescribed therapy and institutional protocol.

For power injection, the implanted port, PowerLoc needle, tubing, connectors, Y-injection site, extension components, and every other device within the complete fluid pathway must be appropriately rated for the intended procedure. The lowest-rated component determines the maximum allowable pressure and flow rate.

Compatibility should be confirmed with the exact implanted port model, septum design, tissue depth, prescribed therapy, infusion pump, power injector, connector system, dressing materials, and institutional vascular-access procedures.

Usage Guidelines

The BD 672234 should be used only by healthcare professionals trained and authorized to access implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and the implanted port manufacturer's directions should be followed throughout the procedure.

• Confirm the patient's identity, prescribed therapy, implanted port type, and power-injection status when applicable.
• Assess the location and depth of the implanted port before selecting the 0.75-inch needle.
• Verify that the 22-gauge configuration provides appropriate flow capability for the intended therapy or imaging procedure.
• Confirm that a Y-injection site is appropriate for the planned clinical workflow.
• Inspect the sterile package for punctures, moisture, damage, contamination, or compromised integrity.
• Prepare the implanted port site according to institutional skin-antisepsis and sterile-access procedures.
• Prime the primary tubing and any intended secondary pathway completely with an approved solution.
• Remove air from the complete fluid pathway before accessing the implanted port.
• Stabilize the implanted port and insert the non-coring needle perpendicular to the septum using an approved technique.
• Advance the needle carefully until appropriate access to the port reservoir is achieved.
• Verify correct needle placement according to institutional policy, including aspiration for blood return when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and facility protocol.
• Position and secure the tubing to minimize pulling, twisting, pressure, and dressing disruption.
• Apply an appropriate sterile dressing while maintaining access-site visibility.
• Disinfect the Y-injection site before every access according to institutional infection-prevention procedures.
• Maintain aseptic technique whenever connecting to or manipulating the Y-injection site.
• Monitor the access site for pain, swelling, redness, leakage, displacement, or other abnormalities.
• Confirm power-injection eligibility before connecting the system to a power injector.
• Do not exceed 2 mL per second or the lower operating limit of any component within the complete vascular-access system.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the port while withdrawing the needle and allowing the safety mechanism to engage.
• Confirm safety lockout through tactile feedback, audible indication, and visual verification.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the vascular-access system if unexpected resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, displacement, or another abnormality develops at the implanted port site.

Certifications and Safety Standards

The BD 672234 PowerLoc Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The device should be incorporated into facility procedures addressing implanted port assessment, hand hygiene, sterile preparation, skin antisepsis, port access, infusion administration, Y-site management, dressing care, power injection, deaccessing, and sharps disposal.

The integrated safety mechanism is designed to help reduce the risk of accidental needle exposure during port deaccessing. As the needle is withdrawn into the base, a protective shield covers the needle point and the needle locks into place.

Tactile feedback, an audible click, and visual confirmation help clinicians verify that safety lockout has occurred before transportation and disposal.

The safety feature supports needlestick-prevention practices but does not replace appropriate clinician training, personal protective equipment, safe sharps handling, exposure-control procedures, or immediate disposal in an approved sharps container.

The non-coring needle should be selected according to patient anatomy, implanted port depth, prescribed therapy, required flow characteristics, and current manufacturer instructions.

Healthcare organizations should review current manufacturer documentation for applicable FDA status, UDI information, sterilization method, material composition, natural rubber latex information, DEHP information, shelf life, maximum pressure, warnings, precautions, contraindications, and other product-specific regulatory requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety technology, the BD PowerLoc system incorporates a mechanism designed to cover and lock the needle point during deaccessing. This supports safer handling between needle withdrawal and final sharps disposal.

Compared with PowerLoc configurations without a Y-injection site, BD 672234 provides an integrated secondary access point within the tubing. This may support compatible intermittent medication administration, flushing, or another approved fluid connection without disconnecting the primary pathway.

Compared with non-power-injectable port-access devices, the PowerLoc platform supports compatible power-injection procedures when used with an appropriately rated implanted port and complete vascular-access system.

Compared with 19-gauge and 20-gauge PowerLoc configurations, the 22-gauge needle provides a smaller external profile but lower maximum power-injection flow capability. The 22-gauge configuration supports up to 2 mL per second, while larger-gauge PowerLoc options may support higher flow requirements.

Compared with 1-inch and 1.5-inch access needles, the 0.75-inch configuration provides a lower access profile for implanted ports positioned closer to the skin surface. Correct needle-length selection supports complete septum access, device stability, securement, and effective dressing placement.

Alternative safety infusion sets may vary in gauge, needle length, power-injection capability, Y-site configuration, tubing length, priming volume, safety activation method, hub design, and package quantity. BD 672234 combines a 22-gauge, 0.75-inch non-coring needle with a Y-injection site, approximately 8-inch tubing, 0.4 mL priming volume, integrated safety technology, and power-injection capability up to 2 mL per second.

Typical User Profile and Application Scenarios

The BD 672234 PowerLoc Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified healthcare personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, emergency departments, specialty practices, and other healthcare facilities where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port can be appropriately accessed with a 0.75-inch needle and whose prescribed treatment or diagnostic procedure is compatible with a 22-gauge device.

Typical application scenarios include medication infusion, antibiotic therapy, hydration, selected chemotherapy treatments, parenteral nutrition, blood specimen collection, routine implanted port maintenance, and compatible power-injection procedures during diagnostic imaging.

The integrated Y-injection site is particularly useful in workflows requiring secondary access for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway.

Best Practices for Use and Maintenance

The BD 672234 is a sterile, single-use medical device. Best practices focus on proper storage, accurate product selection, sterile preparation, implanted port access, Y-site management, site monitoring, power-injection verification, safety activation, and disposal.

• Store unopened sets according to current manufacturer-recommended environmental conditions.
• Protect packages from moisture, excessive temperatures, crushing, punctures, and contamination.
• Rotate inventory according to expiration dates and facility stock-control procedures.
• Verify the BD 672234 or manufacturer SKU 0672234 before opening the package.
• Confirm the 22-gauge size, 0.75-inch needle length, and presence of the Y-injection site.
• Assess the patient's tissue depth and implanted port position before selecting the needle length.
• Confirm that the prescribed therapy and required flow characteristics are appropriate for a 22-gauge access device.
• Use strict aseptic technique during preparation, priming, insertion, connection, and dressing application.
• Prime the complete fluid pathway before accessing the implanted vascular port.
• Consider the approximately 0.4 mL priming volume when precise fluid management is clinically important.
• Stabilize the implanted port during both needle insertion and removal.
• Position the tubing to minimize pulling, twisting, or pressure at the access site.
• Disinfect the Y-injection site according to institutional protocol before every access.
• Keep unused access points appropriately protected from contamination.
• Monitor the implanted port site and tubing connections throughout therapy.
• Verify that the entire vascular-access system is appropriately rated before any power-injection procedure.
• Do not exceed 2 mL per second or the lowest pressure or flow-rate limit of any component within the complete system.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Do not reuse, clean, resterilize, or reprocess the single-use device.
• Confirm complete safety activation immediately after needle withdrawal.
• Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 672234 PowerLoc Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

Before use, verify the product identity, 22-gauge size, 0.75-inch needle length, Y-injection site configuration, sterile package integrity, expiration date, and compatibility with the implanted vascular port. Do not use a device that is expired, damaged, contaminated, or supplied in compromised packaging.

The set should not be used for power injection unless the implanted port and every component within the complete fluid pathway are specifically rated for the intended procedure. Permitted pressure, flow rate, contrast-media characteristics, and other operating conditions must be confirmed before use.

BD identifies manufacturer SKU 0672234 with a maximum power-injection flow rate of 2 mL per second. The lowest-rated component within the complete vascular-access system determines the actual maximum allowable operating limit.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may contribute to infiltration, extravasation, leakage, tissue injury, implanted port damage, interrupted therapy, or other complications.

The Y-injection site should be accessed only with compatible devices using appropriate disinfection and aseptic technique. Improper manipulation or inadequate disinfection may increase the risk of contamination, connection problems, or bloodstream infection.

The integrated safety mechanism should be activated according to current manufacturer instructions. The device remains a contaminated sharp following deaccessing and should be discarded immediately in an approved sharps container.

BD 672234 is supplied 20 sets per case with a minimum order quantity of one case according to the manufacturer listing. Purchasing personnel should confirm current availability, storage requirements, shipping eligibility, order quantities, and applicable return conditions before purchasing.

How to Order

Select the BD 672234 - PowerLoc Safety Infusion Set with Y-Injection Site, 22G x 0.75" and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.